Show simple item record

dc.contributor.authorYamazaki, Takahiro
dc.contributor.authorWennerberg, Erik
dc.contributor.authorHensler, Michal
dc.contributor.authorBuqué, Aitziber
dc.contributor.authorKraynak, Jeffrey
dc.contributor.authorFucikova, Jitka
dc.contributor.authorZhou, Xi Kathy
dc.contributor.authorRekdal, Øystein
dc.contributor.authorDemaria, Sandra
dc.contributor.authorGalluzzi, Lorenzo
dc.date.accessioned2022-03-07T12:52:55Z
dc.date.available2022-03-07T12:52:55Z
dc.date.issued2021-08-10
dc.description.abstractLTX-315 is a nonameric oncolytic peptide in early clinical development for the treatment of solid malignancies. Preclinical and clinical evidence indicates that the anticancer properties of LTX-315 originate not only from its ability to selectively kill cancer cells, but also from its capacity to promote tumortargeting immune responses. Here, we investigated the therapeutic activity and immunological correlates of intratumoral LTX-315 administration in three syngeneic mouse models of breast carcinoma, with a focus on the identification of possible combinatorial partners. We found that breast cancer control by LTX-315 is accompanied by a reconfiguration of the immunological tumor microenvironment that supports the activation of anticancer immunity and can be boosted by radiation therapy. Mechanistically, depletion of natural killer (NK) cells compromised the capacity of LTX-315 to limit local and systemic disease progression in a mouse model of triple-negative breast cancer, and to extend the survival of mice bearing hormone-accelerated, carcinogen-driven endogenous mammary carcinomas. Altogether, our data suggest that LTX-315 controls breast cancer progression by engaging NK cell-dependent immunity.en_US
dc.identifier.citationYamazaki, Wennerberg, Hensler, Buqué, Kraynak, Fucikova, Zhou, Sveinbjørnsson, Rekdal, Demaria, Galluzzi. LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells. Oncoimmunology. 2021;10(1)en_US
dc.identifier.cristinIDFRIDAID 2005683
dc.identifier.doi10.1080/2162402X.2021.1962592
dc.identifier.issn2162-4011
dc.identifier.issn2162-402X
dc.identifier.urihttps://hdl.handle.net/10037/24304
dc.language.isoengen_US
dc.publisherTaylor & Francisen_US
dc.relation.journalOncoimmunology
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.titleLTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cellsen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record